Home>Topics>Companies>AstraZeneca

AstraZeneca

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. AstraZeneca keeps 2015 outlook after financial reporting change

    Headlines

    Fri, 6 Mar 2015

    LONDON, March 6 (Reuters) - Drugmaker AstraZeneca said on Friday it would change the way it reported results with effect from the first quarter of 2015 to make revenue from so-called externalisation deals more visible to investors.

  2. BRIEF- AstraZeneca refines financial reporting from Q1 2015

    Headlines

    Fri, 6 Mar 2015

    * Will see revenue from externalisation becoming more visible to enhance transparency for investors

  3. BRIEF- AstraZeneca completes buy of Actavis' portfolio in North America

    Headlines

    Tue, 3 Mar 2015

    * Completed transaction to acquire rights to actavis' branded respiratory business in us and canada. Source text for Eikon: Further company coverage:

  4. AstraZeneca to carve out antibiotic R&D into separate firm

    Headlines

    Fri, 27 Feb 2015

    LONDON (Reuters) - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.

  5. UPDATE 1- AstraZeneca to carve out antibiotic R&D into separate firm

    Headlines

    Fri, 27 Feb 2015

    LONDON, Feb 27 (Reuters) - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy...

  6. AstraZeneca carving out antibiotic R&D into separate firm

    Headlines

    Fri, 27 Feb 2015

    LONDON, Feb 27 (Reuters) - Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy...

  7. BRIEF-Knowit says wins order from Astrazeneca

    Headlines

    Wed, 25 Feb 2015

    * Knowit ab says wins order from astrazeneca Further company coverage: (Reporting by Daniel Dickson)

  8. AstraZeneca taps biotech firm Orca for autoimmune disease drugs

    Headlines

    Wed, 25 Feb 2015

    LONDON, Feb 25 (Reuters) - AstraZeneca has boosted its early-stage research in autoimmune disease by signing a three-year research deal with start-up firm Orca Pharmaceuticals, a small British biotech company formed in 2013, on a new class of drugs.

  9. Ex-divs to take 10.73 points off FTSE 100 on Feb. 19

    Headlines

    Mon, 16 Feb 2015

    payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by market-makers would take 10.73 points off the index. COMPANY (RIC) DIVIDEND STOCK OPTION MAX (pence) IMPACT ASTRAZENECA

« Prev12345Next »
Content Partners